文献速递胸部PETCT

术前FDG PET/CT的使用与可切除非小细胞肺癌患者生存的关系

Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer.
PubMed 文献 · Radiology · 2022-06-21

该回顾性研究基于台湾癌症登记库纳入2009年1月1日至2018年12月31日接受胸外科手术的可切除I-IIIB期非小细胞肺癌患者,按是否术前行氟18氟代脱氧葡萄糖PET/CT分为两组并进行1:1倾向性评分匹配。匹配后行PET/CT组与未行PET/CT组各6754例,中位随访至2019年12月31日。调整分析显示IIIA期(HR=0.90,95%CI:0.79,0.94,P=0.02)和IIIB期(HR=0.80,95%CI:0.71,0.90,P<0.01)患者行术前PET/CT与较低死亡风险相关,而I-II期未见死亡风险降低(HR=1.19,95%CI:0.89,1.30,P=0.65)。

要点

  • IIIA期可切除非小细胞肺癌术前行PET/CT者死亡风险较低(HR=0.90,P=0.02)。
  • IIIB期可切除非小细胞肺癌术前行PET/CT者死亡风险较低(HR=0.80,P<0.01)。
  • I-II期患者术前行PET/CT未见死亡风险降低(HR=1.19,P=0.65)。

核心结论

  • 在可切除IIIA-IIIB期非小细胞肺癌患者中,术前行PET/CT与较低的死亡风险相关,而I-II期患者未见此关联。

研究设计与样本

  • 回顾性研究,纳入台湾癌症登记库2009年1月1日至2018年12月31日接受胸外科手术的可切除I-IIIB期非小细胞肺癌患者,按是否术前行氟18氟代脱氧葡萄糖PET/CT分组,以未行术前影像者为对照组,按1:1倾向性评分匹配,匹配变量包括性别、年龄、组织学、AJCC临床分期、cT分期、cN分期、现在和既往吸烟史、辅助化疗、辅助放化疗、Charlson合并症指数和医院类型。

诊断标准与关键数值

  • 匹配队列中行PET/CT组6754例(男性3349例,平均年龄64岁±11),未行PET/CT组6754例(男性3362例,平均年龄64岁±11)。
  • 调整分析中IIIA期患者行术前PET/CT较未行者死亡风险更低(HR=0.90,95%CI:0.79,0.94,P=0.02)。
  • 调整分析中IIIB期患者行术前PET/CT较未行者死亡风险更低(HR=0.80,95%CI:0.71,0.90,P<0.01)。
  • 多变量调整后I-II期患者行术前PET/CT未见死亡风险降低(HR=1.19,95%CI:0.89,1.30,P=0.65)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The added value of preoperative PET/CT for the overall survival of patients with resectable non-small cell lung cancer (NSCLC) is unknown. Purpose To investigate the association of the use of preoperative PET/CT on survival of patients with resectable stage I-IIIB NSCLC. Materials and Methods In this retrospective study, patients with resectable stage I-IIIB NSCLC who underwent thoracic surgery from January 1, 2009, to December 31, 2018, from the Taiwan Cancer Registry were included. The last follow-up date was December 31, 2019. Patients were categorized into two groups according to whether they underwent preoperative metabolic imaging with fluorine 18 fluorodeoxyglucose PET/CT. Patients who did not undergo preoperative imaging were used as the control group. The primary outcome of interest was all-cause mortality. Patients in both groups were propensity score matched at a ratio of 1:1. Matching variables used were sex, age, histologic findings, American Joint Committee on Cancer clinical stage, cT stage, cN stage, current and past smoker history, adjuvant chemotherapy, adjuvant chemoradiation, Charlson comorbidity index, and hospital type. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank test. Results In the matched cohort, 6754 patients (3349 men, mean age ± SD: 64 years ± 11) underwent PET/CT and 6754 did not (3362 men, mean age: 64 years ± 11). In adjusted analysis, patients with stage IIIA or IIIB NSCLC and preoperative PET/CT had a lower risk of death versus those without PET/CT (for stage IIIA: hazard ratio [HR] = 0.90 [95% CI: 0.79, 0.94], P = .02; for stage IIIB: HR = 0.80 [95% CI: 0.71, 0.90], P < .01). There was no improvement in a lower risk of death for patients with stage I-II NSCLC (after multivariable adjustment, the HR was 1.19 [95% CI: 0.89, 1.30], P = .65). Conclusion Use of preoperative PET/CT was associated with lower risk of death in patients with stage IIIA-IIIB non-small cell lung cancer compared with those without preoperative PET/CT. © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Chen, Chen, Hsu, et al. Use of Preoperative FDG PET/CT and Survival of Patients with Resectable Non-Small Cell Lung Cancer. Radiology. 2022. PMID: 35727156. doi:10.1148/radiol.212798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。